Mary Radomski

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Mary Radomski sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials none currently recruiting 2 completed upper half by trial count

Mary Radomski: 2 sponsored US clinical trials, none currently recruiting.

Mary Radomski sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. The most-studied condition in this pipeline is Breast Neoplasm, with 1 trials.

Mid-pack sponsor footprint

Mary Radomski is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Indexed trials (enrollment closed)

2 total, page 1 of 1

COMPLETED NA

Feasibility of a Purpose in Life Renewal Intervention for Adults With Persistent Symptoms After Concussion

NCT05780658
COMPLETED NA

Feasibility of Providing a Purpose Renewal Intervention for Cancer Survivors Via Virtual Groups

NCT04767464

Therapeutic Areas

Breast Neoplasm 1
Breast Cancer 1

How the Mary Radomski archive is shaped

2 indexed studies, none listed as recruiting (0% open); 2 completed (100%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Breast Neoplasm (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Mary Radomski: archived-pipeline peers nationwide

Peers matched on 2 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Mary Radomski sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share Mary Radomski1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
Mary Radomski sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Mary Radomski sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Mary Radomski page

2 registered trials is a research-attention snapshot, not an endorsement of Mary Radomski or any single study.

  • None of Mary Radomski's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Breast Neoplasm is the condition Mary Radomski studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Neoplasm trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Mary Radomski pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.